Quanterix, Innovita expand China diagnostics partnership with NMPA approvals for SIMOA instruments, neurology assays

QTRX•2026-10-07

Quanterix expanded its China commercialization arrangement with Innovita after the partner secured NMPA clearances for the HD-X and SR-X instruments and four neurology biomarker kits. Innovita plans additional regulatory filings for Quanterix diagnostic kits.

1. China clearances

NMPA cleared Quanterix’s HD-X and SR-X instruments for the Chinese in vitro diagnostics market, enabling wider rollout of SIMOA systems. Clearances also covered four neurology biomarker kits for blood-based Alzheimer’s testing and disease monitoring applications.

2. Further filings planned

Innovita plans additional China regulatory filings for more Quanterix biomarker diagnostic kits under the partnership.

Quanterix, Innovita expand China diagnostics partnership with NMPA approvals for SIMOA instruments, neurology assays

1. China clearances

2. Further filings planned

Related News

Shake Shack to enter Brazil through licensing partnership with Bold Hospitality

Halozyme wins Dutch injunction blocking Merck Keytruda SC in eight European markets over EP622 patent

Launch Two Acquisition postpones shareholder meeting to Oct. 8

Trio-Tech wins $4.45 million three-year burn-in equipment contract from European automotive chip customer

DeFi Development Corp CEO, strategy chief to present at Maxim Growth Summit